{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Other"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001004829"],"host":["EGA"],"description":["EGA study EGAS00001004829"],"dataset_title":["Single cell RNA sequencing of tumor and ascites in high grade ovarian cancer"],"repository":["EGA"],"category":["restricted"],"name_synonyms":["ascites fluid, Single-Cell RNA-Seq, Single-Cell RNAseq, Malignant Neoplasm, Sc RNAseq, Single Cell Gene Expression Profiling, Neoplasms, Single-Cell Gene Expression Profiling, Benign Neoplasm, scRNA-seq, ascites, ScRNA seq, Single Cell Gene Expression Analysis, Tumor, Malignant, Single-Cell, Single Cell Transcriptome Analysis, Sc-RNAseq, single cell RNA sequencing, Benign, single-cell transcriptome sequencing, single-cell RNA-seq, Neoplasm, Seqs, Analysis, Seq, Single-Cell RNA, Single-Cell Transcriptome Analyses, ScRNAseq, Single-Cell Transcriptome Analysis, Analyses, Malignancy, Peritoneal effusion, Benign Neoplasms, Single Cell RNAseq, Single Cell RNA Seq, Cancers, Transcriptome Analysis, RNA Seq, Single-Cell RNA Seq, Transcriptome Analyses, Malignant Neoplasms, ScRNA-seq, Neoplasias, Single-Cell Transcriptome, RNAseq, Malignancies, RNA-Seq, ascitic fluid, Accumulation of fluid in the abdomen., other neoplasm, Neoplasia, Cancer, Tumors"],"description_synonyms":["biochemical pathways, nicotinamidum, Tumor Necrosis Factor Ligand Superfamily Member 2, Materials, T-cell surface antigen T4/Leu-3, RNA Sequence Determination, Activity, 3-Pyridinecarboxamide, N(1)-methylnicotinamide, Sequence Determination, Glukose, RNA Sequence, Metabonomic, ascites, Monohydrate, Metabonomics, Profiles, T-Lymphocyte, (DL)-Isomer, Tumor, dmTAF[[II]]230, L3T4, primary metabolites, Nicobion, T Lymphocyte, S Amet, Dextrose, Ly-4, B3, Flow Microfluorimetry, vitamin B3, Analysis, FO-1561, Tumor Microenvironments, Cell Sortings, immature T cell, Metabolic Profiles, Ademetionine, treatment, Man (Taxonomy), TFIID TAF250, beta-pyridinecarboxamide, Fluorescence Activated Cell Sorting, Analyses, Cachectin-Tumor Necrosis Factor, cel, Determination, catabolism, S-adenosylmethionine, T-Cells, T, Bodily, pyridinium, S-(5'-deoxyadenosin-5'-yl)-L-methionine, elevated, 3 Pyridinecarboxamide, Sequence Determinations, Nicotinamid, TNF Superfamily, DL-glucose, Niacinamide, glucose, T Cells, Secretion, malignant neoplasm, Secretions, disease management, Therapies, TNFSF2, Nicotinsaeureamid, biotransformation, Malignancies, ascitic fluid, Thymus Dependent Lymphocytes, Flow Cytofluorometry, Accumulation of fluid in the abdomen, inner salt, Tumors, Cancer Microenvironments, ascites fluid, Therapy, Cell Sorting, dTAF[[II]]230, Fluorescence-Activated Cell Sorting, S-Adenosyl-L-Methionine, T-cell surface antigen T4|Leu-3, external secretion, Modern, TAF200, Nicotinamide-S-Adenosylmethionine, TNFA, N-Methyltransferase, TAFII-250, TAF250/230, N1-methylnicotinamide, Determinations, SAMe, Microfluorimetry, trigonellinamide, exocrine gland fluid/secretion, Bodily Secretion, TAFII250, Benign, niacin, T-Cell, nicotinic acid amide, Nicotinamide Methyltransferase, Genetic Materials, secretion, N-1-methylnicotinamide, (alpha-D)-Isomer, Genetic Material, D-Glucose, Vitamin B3, T-cell, Cytofluorometries, Methylase, Vitamin, Immunotherapies, T-cell surface glycoprotein CD4, p32, Thymus-Dependent, Benign Neoplasms, CD4mut, Nicotinamide Methylase, INSDC_feature:gene, TNFalpha, N(1)-methylnicotinamide methylsulfate, 3-pyridinecarboxamide, CG17603, Fluorescence-Activated Cell, TAF[[II]], 5-dideoxy-beta-D-ribofuranos-5-yl][(3S)-3-amino-3-carboxypropyl](methyl)sulfonium, Treatments, human, Thymus-Dependent Lymphocyte, Malignant Neoplasms, N(1)-methylnicotinamide iodide, Adenosine, T cell, N(1)-Methylnicotinamide, Patient, Taf250, nicotinic amide, D Glucose, Material, SR3-5, metabolites, Cells, Biocatalyst, Vitamin PP, Cistron, T Cell, other neoplasm, Glucose Monohydrate, exocrine gland secretion, N(1)-methylnicotinamide cyanide, S Adenosylmethionine, TAF230, Fibroblast, m-(aminocarbonyl)pyridine, Malignant Neoplasms., gluco-hexose, 3-(aminocarbonyl)-1-methyl-, Nicotinamide S Adenosylmethionine Methyltransferase, d230, Nikotinsaeureamid, TNF-alpha, Thymus-Dependent Lymphocytes, human being, exocrine gland fluid, Microenvironment, Glucose, exocrine gland fluid or secretion, Biocatalysts, Neoplasms, infiltrating, Benign Neoplasm, Enduramide, secondary metabolites, Gene, dTAFII250, Catalyses, Cachectin Tumor Necrosis Factor, [1-(adenin-9-yl)-1, Malignant, EfW1, 1-methylnicotinamide cation, Trigonellinamide, Vitamin B 3, pyridine-3-carboxylic acid amide, Human, Fluorescence-Activated, Fluorescence-Activated Cell Sortings, Microfluorometry, S Adenosyl L Methionine, Homo sapiens, Cancer Microenvironment, dmTAF1, Taf230, AdoMet, Metabolomic, 1-methyl-3-carbamoylpyridinium, MAL, Metabolic Profile, Nicotinamide, Man, Tumor Necrosis Factor, Cytofluorometry, TAF250, Nicotinsäureamid Jenapharm, Taf200, dTAF[[II]]250, Methyltransferase, Genetic, Malignancy, Peritoneal effusion, Flow Cytofluorometries, FO 1561, Metabolomes, cell, Profile, Microfluorometries, Papulex, Taf1p, nicotine acid amide, Sequencing, Neoplasias, dTAF250, N(1)-methylnicotinamide perchlorate, secreted substance, Enzyme, SAM-e, Member 2, RNA Sequence Analyses, bodily secretion, Clients, mature T cell, S-Adenosylmethionine, Flow, Flow Microfluorometries, Cytometry, RNA Sequencing, malignant ovarian serous tumour, 1-methylnicotinamide, serous ovarian cancer, TAF, high elevation, T Lymphocytes, Anhydrous, 3-(aminocarbonyl)-1-methylpyridinium, Lymphocyte, Cytometries, Sortings, Cancer, Sequence Analyses, Gumbaral, (3S)-, nicotinamida, RNA, 5'-((3-amino-3-carboxypropyl)methylsulfonio)-5'-deoxy-, TAF[[II]]250, nicotinamide, niamide, Malignant Neoplasm, (beta-D)-Isomer, nicotine amide, degradation, RNA Sequence Determinations, Tumor Necrosis Factor alpha, 1-methyl nicotinamide, Leu2, l(3)84Ab, Flow Cytometries, BG:DS00004.13, (3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine, trigonellamide chloride, Cistrons, Client, N(1)-methylnicotinamide chloride, Cell, dTAF230, 3-(aminocarbonyl-13C)-labeled, uptake, Nicotinamide N Methyltransferase, Samyr, Cytokine, MT, T-cell differentiation antigen L3T4, N(1)-methylnicotinamide tetrafluoroborate (1-), p230, 3-carbamoyl-1-methylpyridin-1-ium, 3-carbamoylpyridine, Neoplasm, TAF[[II]]250/230, TFIID, Flow Microfluorometry, Jenapharm, T lymphocyte, SAM, Taf[[II]]250, N(1)-methylnicotinamide bromide, Cachectin, primary cancer, TAF[[II]]230, Nikotinamid, Acylcarnitine, biodegradation, Metabolic, FO1561, N(1)-methylnicotinamide fluoride, Nicotinamide-S-Adenosylmethionine Methyltransferase, metabolite, B 3, Lymphocytes, TAF[II]250, Cancers, nicotylamide, malignant tumor, Anhydrous Dextrose, Nicotinsäureamid, DmelCG17603, S-Adenosylmethionine Sulfate Tosylate, Therapeutic, RNA Sequence Analysis, Modern Man, Sorting, CD4, Treatment, CD8, Microenvironments, General activity, Neoplasia, S Adenosylmethionine Sulfate Tosylate, TAF1, Glc"],"additional_accession":[]},"is_claimable":false,"name":"scRNA-seq of HGSC tumor and ascites","description":"Immune regulatory metabolites are key features of the tumor microenvironment (TME), yet with a few notable exceptions, their identities remain largely unknown. We uncovered the immune regulatory metabolic states and metabolomes of sorted tumor and stromal, CD4+, and CD8+ cells from the tumor and ascites of patients with high-grade serous ovarian cancer (HGSC) using high-dimensional flow cytometry and metabolomics supplemented with single cell RNA sequencing. Flow cytometry revealed that tumor cells show a consistently greater uptake of glucose than T cells, but similar mitochondrial activity. Cells within the ascites and tumor had pervasive metabolite differences, with a striking enrichment in 1-methylnicotinamide (MNA) in T cells infiltrating the tumor compared to ascites. Despite the elevated levels of MNA in T cells, the expression of nicotinamide N-methyltransferase, the gene encoding the enzyme that catalyses the transfer of a methyl group from S-adenosylmethionine to nicotinamide, was restricted to fibroblasts and tumor cells. Treatment of T cells with MNA resulted in an increase in T cell-mediated secretion of the tumor promoting cytokine tumor necrosis factor alpha. Thus, the TME-derived metabolite MNA contributes to an alternative and non-cell autonomous mechanism of immune modulation of T cells in HGSC. Collectively, uncovering the tumor-T cell metabolome may reveal metabolic vulnerabilities that can be exploited using T cell-based immunotherapies to treat human cancer.","dates":{"updated":"2022-12-12 11:10:02"},"accession":"EGAS00001004829","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001006627","EGAC00000000011"]}}